Effects of 1 MHz Therapeutic Ultrasound on Limb Blood Flow and Microvascular Reactivity: A Randomized Pilot Trial

A randomized, double-blind, placebo-controlled, cross-over study where continuous therapeutic ultrasound (CUS; at 0.4 W/cm²), pulsed therapeutic ultrasound (PUS; at 20% duty cycle, 0.08 W/cm²), both at 1 MHz, and placebo (equipment on, no energy provided) were randomized and applied over the forearm of the non-dominant arm for 5 min in 10 young, healthy individuals. Absolute and peak forearm blood flow (FBF) were measured via Venous Occlusion Plethysmography. FBF was measured before, halfway, and after (immediately and 5 min after) the therapeutic ultrasound (TUS) intervention. Post-ischemic peak FBF was measured 10 min before and 10 min after the TUS intervention. A two-way repeated measures ANOVA (group × time) was selected to assess differences in FBF before, during, and after TUS treatment, and for peak FBF before and after TUS treatment. FBF increased 5 min after TUS in CUS compared to placebo (2.96 ± 1.04 vs. 2.09 ± 0.63 mL/min/100 mL of tissue, p < 0.05). PUS resulted in the greatest increase in Peak FBF at 10 min after US (Δ = 3.96 ± 2.02 mL/min/100 mL of tissue, p = 0.06). CUS at 1 MHz was an effective treatment modality for increasing FBF up to 5 min after intervention, but PUS resulted in the greatest increase in peak FBF at 10 min after intervention.

Differences between Males and Females in Determining Exercise Intensity

Even though there are physiological differences between males and females, heart rate (HR), ratings of perceived exertion (RPE), power output (PO), oxygen consumption (VO2), and blood lactate (BL) levels have been used as measures of exercise intensity independently of sex. The purpose of this study was to determine differences between sexes in different exercise intensity models. Thirty (15 females) young, healthy individuals were scheduled for two testing visits 48-72 hours apart. During the first testing visit, a graded exercise test (GXT), with BL obtained at the end of each exercise step, was administered on a stationary bicycle to determine peak PO and VO2max. BL during the GXT was used to determine three 5-min steady-state workloads (low: 0-2 mmol/L; moderate: 2-4 mmol/L; and high: >4 mmol/L) for the second test. HR, %HRmax, RPE, PO, %POmax, VO2, %VO2max, and BL were obtained at the end of each steady-state workload. A two-way repeated measures ANOVA was performed to compare all exercise intensity variables obtained during the second test between males and females (α=0.05). Only RPE, %PO, and BL did not differ between sexes on all 3 exercise intensities. HR, %HR, and PO differ between sexes on at least 2 exercise intensities. Females have higher HR and %HR than males for similar %PO. VO2 and %VO2max differ between sexes on at least 1 exercise intensity. Based on the current results, traditional exercise intensity markers are different between males and females. BL and %PO appear to be markers that might be used independently of sex.

Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only

Fanconi anemia (FA) is a genomic instability syndrome associated with bone marrow failure, myelodysplastic syndrome (MDS), and/or acute myeloid leukemia (AML) requiring hematopoietic stem cell transplantation (HSCT) to restore normal hematopoiesis. Although low-intensity fludarabine-based preparative regimens without radiation confer excellent outcomes in FA HSCTs with HLA-matched sibling donors, outcomes for FA patients with alternative donors are less encouraging, albeit improving. We present our experience with 17 FA patients who completed mismatched related or unrelated donor HSCT using a non-radiation fludarabine-based preparative regimen at Charité University Medicine Berlin. All patients engrafted; however, one patient had unstable chimerism in the setting of multi-viral infections that necessitated a stem cell boost to revert to full donor chimerism. Forty-seven percent of patients developed grade I acute graft-verus-host disease (aGVHD). No grade II-IV aGVHD or chronic graft-versus-host disease of any severity occurred. At a median follow-up of 30 months, 88 % of patients are alive with normal hematopoiesis. Two patients died of infections 4 months post-transplantation. These results demonstrate that short-term outcomes for FA patients with mismatched and unrelated donor HSCTs can be excellent using chemotherapy only conditioning. Viral reactivation, however, was a major treatment-related complication.

The state of research into children with cancer across Europe: new policies for a new decade

Overcoming childhood cancers is critically dependent on the state of research. Understanding how, with whom and what the research community is doing with childhood cancers is essential for ensuring the evidence-based policies at national and European level to support children, their families and researchers. As part of the European Union funded EUROCANCERCOMS project to study and integrate cancer communications across Europe, we have carried out new research into the state of research in childhood cancers. We are very grateful for all the support we have received from colleagues in the European paediatric oncology community, and in particular from Edel Fitzgerald and Samira Essiaf from the SIOP Europe office. This report and the evidence-based policies that arise from it come at a important junction for Europe and its Member States. They provide a timely reminder that research into childhood cancers is critical and needs sustainable long-term support.